Because the targeting of ERBB3 has the potential to enhance the efficacy of other RTK inhibitors, combinatory treatments with both miR-143/145 and ErbB-targeted drugs may offer a viable strategy for breast cancer therapy. This evidence concerns the gene ERBB3 and breast carcinoma.